Dr. Sage grew up in France. As a student at the École Normale Supérieure in Paris, he studied biology, and then did his PhD at the University of Nice with Dr. François Cuzin and his post-doctoral training at MIT with Dr. Tyler Jacks. He started his own research group at Stanford in 2004 where he is currently the Elaine and John Chambers Professor in Pediatric Cancer and a Professor of Genetics, and where he serves as the co-Director of the Cancer Biology PhD program. For his work on cancer genetics, he has been awarded a Damon Runyon Cancer Research Foundation Scholar Award, a Leukemia and Lymphoma Society Scholar Award, and an R35 Outstanding Investigator Award from the National Cancer Institute. Dr. Sage’s work has focused on the RB tumor suppressor pathway and how inactivation of RB promotes tumorigenesis in children and adults. Dr. Sage became initially interested in small cell lung cancer (SCLC) because of the nearly ubiquitous loss of RB in this cancer type and the intriguing relationship in mice and humans between loss of RB and the growth of neuroendocrine lesions. In the past few years, the Sage lab has developed pre-clinical models for SCLC, including genetically engineered mouse models. His lab has used these models to investigate signaling pathways and cell-cell interactions driving the growth and metastatic ability of this cancer type and to identify novel therapeutic targets in this recalcitrant cancer.